AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...
Headlines,Assetmark Inc. raises stake in AbbVie Inc. (NYSE),Institutional investors boost their positions in AbbVie,Strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback